Amyotrophic lateral sclerosis type 10, or ALS10, is a genetic form of ALS caused by changes (mutations) in a gene called TARDBP. This gene makes a protein named TDP-43 that helps cells read and process genetic messages. When TARDBP is altered, TDP-43 can misbehave. It may leave the cell’s nucleus, clump in the cell body, and stop doing its normal jobs with DNA and RNA. Over time, this hurts the motor neurons—the nerve cells that control muscle movement. As motor neurons die, muscles become weak, thin, and stiff. This leads to problems with walking, hand use, speaking, swallowing, and breathing. ALS10 is usually inherited in an autosomal dominant way (a change in just one copy of the gene can cause disease), and some people also have thinking or behavior changes called frontotemporal dementia (FTD). PMC+3NCBI+3GARD Information Center+3
ALS type 10 (ALS10) is a genetic form of motor neuron disease caused by changes (mutations) in the TARDBP gene. TARDBP makes a protein called TDP-43, which helps cells handle RNA, the instructions that tell cells how to make proteins. In ALS10, the motor nerves in the brain and spinal cord slowly die. As these nerves fail, muscles get weak, tight, and thin, and people have trouble walking, using their hands, speaking, swallowing, and breathing. ALS10 is usually autosomal dominant, which means a parent with the gene change can pass it to a child. Some families with TARDBP changes may also have frontotemporal dementia (FTD) features such as behavior or language changes. Age at onset varies widely. There is no cure yet, but several treatments can slow some problems, ease symptoms, and improve quality of life. NCBI+1
Other names
ALS10
TARDBP-related ALS
Amyotrophic lateral sclerosis 10 with or without frontotemporal dementia
TDP-43–related ALS (because TARDBP encodes the TDP-43 protein) NCBI+2NCBI+2
Types
Limb-onset ALS10
Most people first notice weakness in one hand or foot. They may drop objects, trip, or have foot-drop. Weakness then spreads to other body parts. Doctors find signs from both upper motor neurons (stiffness, brisk reflexes) and lower motor neurons (wasting, fasciculations). NCBIBulbar-onset ALS10
In some, the first problems are speech and swallowing. Words sound slurred (dysarthria) and swallowing is slow or unsafe (dysphagia). These can lead to drooling, weight loss, and choking. NCBI+1ALS10 with frontotemporal dementia (ALS-FTD)
A portion of people with TARDBP changes develop cognitive and behavior changes—for example, apathy, poor judgment, language trouble, or personality change—together with motor symptoms. NCBIALS10 with parkinsonism (less common)
Some individuals show slowness, rigidity, or tremor in addition to ALS features. GARD Information Center
Causes
Important: ALS10 is genetic—the root cause is a disease-causing variant in TARDBP. The items below explain the main cause plus biological mechanisms and possible modifiers that may affect when symptoms start or how fast they progress. Not everyone with a risk factor will get ALS, and not all factors apply to every person.
Pathogenic variants in TARDBP (the core cause)
Specific missense variants (for example, p.A382T, p.I383V) can cause ALS10. NCBI+1TDP-43 misfolding and toxic clumping
Mutant TDP-43 misfolds, forms cytoplasmic aggregates, and harms neurons (toxic “gain of function” and “loss of normal function”). PMCNuclear clearance and cytoplasmic mislocalization
TDP-43 leaves the nucleus (where it should work) and accumulates in the cytoplasm, disturbing cell balance. NatureAbnormal RNA processing and splicing
TDP-43 normally binds RNA. When it is altered, many RNAs are mis-spliced, which can starve neurons of needed proteins. MedlinePlusDisrupted calcium handling and ER stress
TARDBP mutations can reduce endoplasmic-reticulum Ca²⁺ signaling and stress motor neurons. NatureImpaired protein clearance (autophagy/ubiquitin proteasome)
Cells may fail to clean up misfolded proteins, letting toxic clumps accumulate. (Inference consistent with TDP-43 proteinopathy literature.) PMCMitochondrial dysfunction
Sick mitochondria make less energy and more free radicals, adding stress to motor neurons. (Inference supported by TDP-43 pathology frameworks.) PMCAxonal transport failure
Long motor axons depend on fast transport. TDP-43 changes may derail this system. (Mechanistic inference from TDP-43 biology.) PMCGlutamate excitotoxicity
Overactive glutamate signals can overwork and injure motor neurons. (General ALS mechanism described in reviews.) NCBINeuroinflammation
Activated glia and inflammatory mediators can worsen injury. (General ALS concept.) NCBIAge
ALS risk rises with age; TARDBP-ALS often begins in adulthood. NCBIMale sex (population trend)
Men are diagnosed with ALS more often than women; this may modify risk or timing. NCBIFamily history of ALS or FTD
Indicates inherited risk in autosomal dominant TARDBP families. NCBICigarette smoking
Repeatedly linked with higher ALS risk in meta-analyses. FrontiersHead injury
Prior head trauma is associated with higher ALS risk in pooled studies. Frontiers+1Exposure to pesticides/solvents/heavy metals
Several analyses show associations with ALS risk. Frontiers+1Military service (complex, debated)
Multiple reviews and meta-analyses report a modestly increased risk in veterans. PMC+1High, strenuous physical activity (debated)
Some studies link heavy lifetime exertion with ALS; evidence is mixed. The Lancet+2Oxford Academic+2Electric shock
Reported as a possible risk factor in case–control work. FrontiersCyanobacterial toxins (BMAA) and other environmental sources (under study)
Investigations continue on water-body exposures and toxins. CDC
Symptoms
Muscle weakness that often starts in one hand or foot (dropping things, tripping). NCBI
Muscle wasting (atrophy)—muscles look smaller over time. NCBI
Muscle twitches (fasciculations)—fine rippling under the skin. NCBI
Muscle cramps—painful tightening, especially at night. NCBI
Stiffness and spasticity—tight muscles, trouble relaxing. NCBI
Over-active reflexes and Babinski sign (toes go up when foot sole is stroked). NCBI
Slurred or nasal speech (dysarthria)—words sound unclear. NCBI
Swallowing problems (dysphagia)—choking, coughing with meals. GARD Information Center
Drooling—from weak lip and throat control. NCBI
Breathlessness, especially when lying flat or with activity—weak breathing muscles. NCBI
Weight loss—from muscle loss and swallowing trouble. NCBI
Head-drop or poor neck hold—neck extensor weakness. NCBI
Emotional lability (pseudobulbar affect)—sudden crying or laughing. NCBI
Cognitive or behavioral change—apathy, poor judgment, language issues in ALS-FTD. NCBI
Parkinsonism features (less common)—slowness, rigidity. GARD Information Center
Diagnostic tests
Note: ALS is a clinical diagnosis supported by tests that show motor-neuron involvement and exclude look-alike conditions. Many centers now use the Gold Coast criteria (2019) to diagnose ALS earlier and more simply than older El Escorial/Awaji rules. Genetic testing confirms TARDBP in ALS10. BMJ Paediatrics+2PMC+2
A) Physical examination
Comprehensive neurological exam
The doctor checks strength, reflexes, muscle tone, coordination, and sensation in each region (bulbar, cervical, thoracic, lumbosacral). In ALS10, they often find a mix of upper motor neuron signs (spasticity, brisk reflexes) and lower motor neuron signs (atrophy, fasciculations). This combination across body regions supports the diagnosis. NCBIBulbar function assessment
Speech clarity, swallow safety, tongue movement, and gag reflex are examined. Slurred speech, tongue wasting/fasciculations, and choking episodes suggest bulbar involvement. NCBIRespiratory muscle check
The clinician looks for shallow breathing, use of accessory muscles, and weak cough. Early recognition guides non-invasive ventilation and airway care. NCBI
B) “Manual” bedside/clinic tools
Manual Muscle Testing (MRC scale)
The examiner grades strength (0–5) in many muscles by hand. Serial scores track progression.ALS Functional Rating Scale-Revised (ALSFRS-R)
A 12-item questionnaire (speech, swallow, handwriting, walking, breathing, etc.) that patients answer. It monitors daily-life function and change over time.Bedside swallow screening and speech evaluation
Simple tests (water swallow, observation of coughing/voice) and focused speech-language checks flag aspiration risk and need for formal studies.Pulmonary function at bedside (single breath count, peak cough flow)
Quick checks help decide when to order full respiratory testing. NCBI
C) Laboratory & pathological tests
Serum creatine kinase (CK)
CK may be normal or mildly high from muscle breakdown; very high values suggest other muscle diseases, helping with differential diagnosis. MedscapeVitamin B12 and methylmalonic acid
B12 lack can mimic ALS with weakness and myelopathy; ruling it out avoids misdiagnosis. MedscapeThyroid function tests
Thyroid disorders can cause weakness, cramps, or neuropathy; testing helps exclude mimics. MedscapeSerum protein electrophoresis and immunofixation
Looks for monoclonal proteins linked with neuropathies that can imitate ALS. MedscapeInfection screens when appropriate
Tests for HIV, HTLV-1, Lyme, and syphilis may be ordered based on risk and region, because these can cause motor neuropathies or myelopathies. MedscapeGenetic testing (TARDBP sequencing; panel/expanded testing)
Confirms ALS10 by finding a pathogenic TARDBP variant; panels often include C9orf72, SOD1, FUS and others when family history is unclear. Orpha+1
D) Electrodiagnostic tests
Electromyography (EMG)
EMG shows active denervation (fibrillation/positive sharp waves) and chronic reinnervation in multiple regions, even where weakness is subtle. It strongly supports ALS and is central in the Gold Coast approach. Medscape+2Wiley Online Library+2Nerve conduction studies (NCS)
They help exclude peripheral neuropathies. In ALS, sensory studies are usually normal; motor studies show reduced compound muscle action potentials from axonal loss. MedscapeTranscranial magnetic stimulation (TMS) (when available)
Can reveal upper motor neuron dysfunction by showing corticospinal pathway changes, supporting the clinical picture. ScienceDirectMotor Unit Number Estimation/Index (MUNE/MUNIX)
Research/clinic tools to estimate how many functioning motor units remain; useful for tracking disease burden. ScienceDirect
E) Imaging tests
MRI of brain and spinal cord
MRI usually looks normal in ALS but is essential to rule out look-alikes (cervical/lumbar stenosis, tumors, stroke, multiple sclerosis). It supports a safe, accurate diagnosis. MedscapeChest imaging for aspiration/ventilation issues (when indicated)
X-ray or CT may be used to assess aspiration pneumonia risk or complications in advanced disease (ordered case-by-case). MedscapeSwallow studies (videofluoroscopic or fiberoptic endoscopic evaluation)
These imaging-based tests visualize swallow safety, guide diet/texture changes, and help prevent aspiration. Medscape
Non-pharmacological treatments
(therapies & other supports — each includes description, purpose, and mechanism in simple terms)
Multidisciplinary ALS clinic care
Description: Regular visits with a coordinated team (neurologist, nurse, physio, OT, speech therapist, dietitian, respiratory therapist, social worker).
Purpose: To treat many problems at once, reduce hospital visits, and plan ahead.
Mechanism: Team care spots issues early (nutrition, breathing, mobility), coordinates timely aids (NIV, PEG, communication devices), and provides caregiver education, which together improve quality of life and sometimes survival.Respiratory support with non-invasive ventilation (NIV, e.g., BiPAP)
Description: A mask delivers gentle pressure to help breathing, mostly during sleep, later also in daytime.
Purpose: Relieve fatigue, morning headaches, poor sleep, and breathlessness; prolong life when started at the right time.
Mechanism: Off-loads weak breathing muscles, improves oxygen and carbon dioxide levels, and reduces the strain on the chest wall and diaphragm. High-quality studies show NIV improves survival and quality of life, especially when bulbar function is still fair. PubMed+1Airway clearance (cough-assist / mechanical insufflation–exsufflation, breath stacking, suction)
Description: Devices and techniques to produce a stronger cough and clear mucus.
Purpose: Prevent chest infections and hospitalizations.
Mechanism: These tools boost cough flow to move secretions out when chest muscles are too weak to cough effectively.Speech and swallowing therapy
Description: Exercises, pacing, posture, diet texture changes, and strategies to make speech clearer and swallowing safer.
Purpose: Reduce choking risk, save voice energy, and improve communication.
Mechanism: Compensatory methods (e.g., chin-tuck, smaller sips, thickened liquids) optimize the parts of swallowing that still work and reduce aspiration.Early nutrition planning and weight maintenance
Description: Meeting with a dietitian to plan high-calorie, high-protein intake; consider supplements; monitor weight closely.
Purpose: Maintain energy, slow weight loss, lower risk of complications.
Mechanism: Adequate calories and protein support breathing muscles and overall strength; under-nutrition worsens outcomes in ALS.Feeding tube (PEG/RIG) planning
Description: Discuss and schedule a PEG (percutaneous endoscopic gastrostomy) or radiologically inserted gastrostomy when swallowing gets harder or weight drops.
Purpose: Maintain safe hydration, nutrition, and medication delivery.
Mechanism: A small tube into the stomach bypasses the weak swallow. Timing matters; many guidelines advise considering PEG before breathing capacity is very low (often when FVC is still ≥50%) to reduce risks.Physical therapy (PT)
Description: Gentle range-of-motion, flexibility, and low-to-moderate aerobic activity tailored to energy levels.
Purpose: Reduce stiffness and pain, maintain joint mobility, and slow deconditioning without over-fatigue.
Mechanism: Safe, sub-maximal exercise helps circulation and joint health and can reduce spasticity discomfort.Occupational therapy (OT) & energy conservation
Description: Teach smart ways to do daily tasks (bathing, dressing, cooking), recommend adaptive tools and home modifications (grab bars, ramps).
Purpose: Keep independence longer and reduce caregiver strain.
Mechanism: Simplifies tasks and reduces falls and fatigue.Mobility aids
Description: Braces (AFOs), canes, walkers, tilt-in-space wheelchairs, and powered chairs with head/neck support.
Purpose: Safety, reduced falls, longer community mobility, less energy used.
Mechanism: External support replaces lost muscle strength and protects joints and skin.Communication support (AAC)
Description: From simple notebooks and voice-amplifiers to eye-tracking speech-generating devices.
Purpose: Preserve communication as speech gets softer or slurred.
Mechanism: Technology bypasses weak speech muscles so people can still interact, work, and express preferences.Sialorrhea (drooling) management without pills
Description: Positioning, chin support, oral care, sugar-free gum, portable suction, and speech-therapy strategies.
Purpose: Reduce drooling and aspiration risk, improve comfort.
Mechanism: Mechanical and behavioral steps decrease pooling of saliva.Pain management (non-drug approaches)
Description: Heat, gentle massage, stretching, correct seating/positioning, pressure-relieving cushions and mattresses.
Purpose: Relieve muscle cramps, stiffness, shoulder and neck pain.
Mechanism: Improves blood flow, reduces spasm, and reduces pressure injury risk.Sleep hygiene and daytime routine
Description: Regular sleep times, head-of-bed elevation, cool/dark room, and NIV as prescribed.
Purpose: Reduce morning headaches and fatigue; improve mood and daytime function.
Mechanism: Better sleep and controlled CO₂ levels improve brain and muscle function during the day.Psychological support and counseling (including caregiver support)
Description: Counseling, support groups, and stress-reduction strategies.
Purpose: Manage anxiety, sadness, role changes, and caregiver burnout.
Mechanism: Teaches coping tools; improves adherence to therapies; protects mental health.Mind-body strategies
Description: Mindfulness, breathing exercises, guided imagery, and gentle yoga adapted to ability.
Purpose: Reduce stress, improve comfort and perceived breath control.
Mechanism: Lowers sympathetic arousal, which can ease dyspnea and muscle tension.Advance care planning
Description: Early, honest talks about values and choices: NIV, PEG, tracheostomy, hospital vs home care.
Purpose: Make sure care matches the person’s wishes.
Mechanism: Written plans prevent crisis decisions and reduce distress for families.Palliative care integration
Description: Symptom-focused care delivered alongside usual treatment from early in the disease.
Purpose: Better symptom control, communication, and planning.
Mechanism: Expert support for pain, breathlessness, mood, sleep, and caregiver needs.Fall prevention & home safety
Description: Remove trip hazards, install night lights and grab bars, use non-slip shoes, teach safe transfers.
Purpose: Prevent fractures and hospital stays.
Mechanism: Environmental and behavioral changes reduce risk.Vaccination & infection prevention
Description: Annual flu shot, pneumonia vaccines, hand hygiene; prompt treatment of chest infections.
Purpose: Keep lungs healthier and avoid setbacks.
Mechanism: Reduces respiratory infections that strain weak breathing muscles.Social & financial resources linkage
Description: Help with disability benefits, equipment funding, transport, and respite care.
Purpose: Reduce stress and improve access to necessary supports.
Mechanism: Practical help keeps people at home safely longer.
Drug treatments
Important note: Only a few drugs modify ALS progression. Many medications below treat symptoms. Always individualize doses with a clinician.
Riluzole
Class: Glutamate modulator (benzothiazole).
Dose/Time: 50 mg by mouth every 12 hours (tablet, film, or suspension). Take the same time each day; some products advise empty stomach.
Purpose: Modestly slows disease progression and may extend survival by months.
Mechanism: Lowers glutamate-related nerve toxicity.
Side effects: Nausea, tiredness, elevated liver enzymes (needs blood tests), dizziness.Edaravone (RADICAVA / RADICAVA ORS)
Class: Free-radical scavenger (antioxidant).
Dose/Time: IV 60 mg over 60 minutes in cycles; or oral suspension 105 mg mornings (first cycle: 14 days on/14 off; later cycles: 10 days on/14 off).
Purpose: Slows functional decline in selected patients.
Mechanism: Reduces oxidative stress in motor neurons.
Side effects: Bruising, headache, gait disturbance, allergic reactions; oral form requires fasting schedule.Tofersen (Qalsody®) — for SOD1-ALS only, not ALS10
Class: Antisense oligonucleotide (gene-targeted).
Dose/Time: 100 mg intrathecal (spinal) injection on days 1, 15, 29 (loading), then every 28 days.
Purpose: For confirmed SOD1 mutation ALS; reduces a nerve-injury biomarker (NfL) and may slow decline.
Mechanism: Lowers SOD1 protein production.
Side effects: Headache, back pain, CSF pleocytosis; lumbar puncture risks. Note: Not for TARDBP ALS10, but listed for completeness.Baclofen
Class: Antispasticity (GABA-B agonist).
Dose/Time: Often start 5 mg 1–3×/day; titrate slowly (e.g., up to 20 mg three times daily as tolerated).
Purpose: Eases stiffness and spasms.
Mechanism: Dampens spinal reflexes.
Side effects: Sleepiness, weakness, dizziness; avoid abrupt stop.Tizanidine
Class: α2-adrenergic agonist (antispasticity).
Dose/Time: Start low (e.g., 2 mg at bedtime), increase to effect; often divided doses.
Purpose: Reduces spasticity and painful muscle tone.
Mechanism: Reduces excitatory signals to motor neurons.
Side effects: Sleepiness, dry mouth, low blood pressure, liver enzyme rise.Intrathecal baclofen (ITB) via pump
Class: Antispasticity (intraspinal delivery).
Dose/Time: Continuous pump infusion after trial dose; dosing customized.
Purpose: For severe spasticity not controlled by pills.
Mechanism: Delivers baclofen directly to spinal cord.
Side effects: Infection, pump issues; overdose/withdrawal risks; requires surgery (see procedures below).Mexiletine
Class: Antiarrhythmic used off-label for cramps.
Dose/Time: Commonly 150–300 mg/day in divided doses (doctor adjusts).
Purpose: Reduces muscle cramps in ALS.
Mechanism: Sodium-channel blocker dampening hyperexcitable muscle/nerve firing.
Side effects: Heart rhythm issues in predisposed people, nausea, tremor—requires medical supervision. Evidence from randomized trials supports cramp reduction in ALS.Dextromethorphan/quinidine (Nuedexta®)
Class: NMDA antagonist / CYP2D6 inhibitor combo.
Dose/Time: Titration then 20/10 mg twice daily for pseudobulbar affect (PBA).
Purpose: Reduces uncontrollable laughing/crying episodes.
Mechanism: Modulates brain signaling linked to emotional expression.
Side effects: Dizziness, diarrhea, QT prolongation; drug interactions.Glycopyrrolate
Class: Anticholinergic.
Dose/Time: Low dose, typically 1 mg up to three times daily (varies).
Purpose: Reduces drooling.
Mechanism: Lowers saliva production.
Side effects: Dry mouth, constipation, blurred vision, confusion (less likely than some others because it poorly crosses into the brain).Scopolamine (hyoscine) transdermal patch
Class: Anticholinergic.
Dose/Time: Patch changed every 72 hours.
Purpose: Another option for drooling.
Mechanism: Reduces saliva.
Side effects: Dry mouth, drowsiness, confusion in sensitive people.Atropine 1% ophthalmic drops (sublingual off-label)
Class: Anticholinergic.
Dose/Time: A few drops under tongue as directed.
Purpose: Quick rescue for drooling.
Mechanism: Local anticholinergic effect.
Side effects: Dry mouth, fast heartbeat if too much is absorbed.Botulinum toxin injections to salivary glands
Class: Neurotoxin (local).
Dose/Time: Injections every ~3 months.
Purpose: Strong drooling control when pills fail.
Mechanism: Temporarily blocks saliva-releasing nerve signals.
Side effects: Thick saliva, dry mouth, rare swallowing worsening. Evidence supports benefit in ALS-related sialorrhea.Amtriptyline (low dose)
Class: Tricyclic antidepressant.
Dose/Time: Often 10–25 mg at night.
Purpose: Helps mood, sleep, neuropathic pain, and can reduce drooling.
Mechanism: Serotonin/norepinephrine reuptake inhibition and anticholinergic action.
Side effects: Dry mouth, constipation, drowsiness.SSRIs (e.g., sertraline, citalopram)
Class: Antidepressants.
Dose/Time: Standard depression/anxiety dosing (doctor-guided).
Purpose: Treats depression/anxiety, common in ALS.
Mechanism: Boosts serotonin signaling.
Side effects: Nausea, sleep changes, sexual dysfunction.Gabapentin or pregabalin
Class: Neuropathic pain agents.
Dose/Time: Slow titration to effect.
Purpose: Helps nerve pain, nighttime discomfort, sometimes cramps.
Mechanism: Modulates calcium channels to calm overactive nerves.
Side effects: Drowsiness, dizziness, swelling.Quinine is generally avoided
Class: Antimalarial/antispasmodic.
Dose/Time: —
Purpose/Mechanism: Was used for cramps; not recommended because of heart rhythm and blood risks.
Side effects: Serious adverse effects; most guidelines discourage.Laxatives and stool softeners (e.g., polyethylene glycol)
Class: Osmotic agents.
Dose/Time: Daily as needed.
Purpose: Relieve constipation from reduced mobility and anticholinergic drugs.
Mechanism: Draw water into bowel to ease stools.
Side effects: Bloating, cramps.Short-acting bronchodilators or nebulizers for thick secretions (as advised)
Class: Airway aids.
Dose/Time: As needed.
Purpose: Ease breathlessness from mucus plugs.
Mechanism: Opens airways; sometimes combined with saline or acetylcysteine nebulization to thin mucus.
Side effects: Tremor, rapid heartbeat (bronchodilators).Analgesics (acetaminophen/NSAIDs; opioids when needed)
Class: Pain relievers.
Dose/Time: As per standard dosing.
Purpose: Control musculoskeletal pain and dyspnea (opioids in low doses can ease breathlessness in advanced disease).
Mechanism: Central and peripheral pain pathway modulation.
Side effects: Depending on drug—monitor stomach, kidney, sedation.Edaravone + riluzole together
Class: Combination disease-modifying strategy.
Dose/Time: As above for each drug.
Purpose: Many clinics combine them to maximize modest slowing.
Mechanism: Different protective pathways (glutamate toxicity + oxidative stress).
Side effects: As above for each drug.
Important update about AMX0035 (sodium phenylbutyrate/taurursodiol; RELYVRIO/ALBRIOZA): In April 2024 the manufacturer voluntarily withdrew it from the U.S. and Canadian markets after a phase 3 trial failed; it is not available for new patients in those countries.
Dietary molecular supplements
High-calorie nutrition (overall strategy)
Dose: Individualized; dietitian often targets weight stability or slight gain.
Function/Mechanism: Extra calories and protein can help maintain strength and breathing muscle reserve; observational and small trials suggest fewer complications when weight loss is prevented. Works by countering hyper-metabolism seen in many with ALS.Omega-3 fatty acids (fish oil/DHA-EPA)
Dose: Commonly 1–2 g/day EPA+DHA (check interactions).
Function: Anti-inflammatory support and heart health.
Mechanism: May modulate cell membranes and inflammation pathways; human data in ALS are limited; consider mainly for general health.Vitamin D
Dose: As per blood level; often 800–2000 IU/day (doctor-guided).
Function: Bone and immune support; low levels are common and worsen fall risk.
Mechanism: Hormone-like effects on muscle and bone; ALS outcome data are mixed.Creatine
Dose: Often 3–5 g/day.
Function: Energy buffer for muscles.
Mechanism: Recycles ATP in muscle; clinical trials in ALS have not shown clear functional benefit, but some people feel stronger for daily tasks; safe for many when kidneys are healthy.Coenzyme Q10
Dose: Often 300–1200 mg/day.
Function: Antioxidant/mitochondrial cofactor.
Mechanism: Electron transport support; ALS trials negative for clear benefit.Acetyl-L-carnitine
Dose: 1–3 g/day in divided doses.
Function: Fatty-acid transport into mitochondria; potential energy support.
Mechanism: Mitochondrial shuttle; mixed human data; mainly supportive.Curcumin (turmeric extract)
Dose: Standardized extracts as directed (watch drug interactions).
Function: Anti-inflammatory/antioxidant.
Mechanism: NF-κB and oxidative stress modulation in preclinical work; human ALS evidence is limited.Resveratrol
Dose: 150–500 mg/day commonly used in supplements.
Function: Antioxidant; sirtuin activation (theoretical).
Mechanism: Cellular stress resistance in models; human ALS data lacking.N-acetylcysteine (NAC)
Dose: 600–1200 mg/day (check with doctor).
Function: Mucus thinning and antioxidant precursor (glutathione).
Mechanism: Helps thin thick secretions when nebulized; oral form supports antioxidant defenses.Methylcobalamin (vitamin B12, ultra-high-dose)
Dose: In Japan, 50 mg intramuscularly twice weekly was studied in early ALS (≤12 months from onset), showing slower functional decline over 16 weeks; subsequently approved there. Availability and indications vary by country.
Function/Mechanism: Supports nerve repair reactions; may reduce motor-neuron stress early.
Note: This is not a standard oral vitamin dose; it’s a prescription-strength injection used under specialist guidance.
Immunity / regenerative / stem-cell–oriented drugs
Caution: No stem-cell or “immunity booster” therapy has proven to cure ALS10. What follows are research-or-context items, not standard care.
Tofersen (gene-targeted ASO) — SOD1-ALS only
Intrathecal antisense oligonucleotide that lowers SOD1 protein; FDA-approved for SOD1-ALS with scheduled loading/maintenance dosing. Not for TARDBP ALS10, but it proves gene-targeted therapy can work in ALS.TDP-43/TARDBP-focused strategies (preclinical/early trials)
Multiple labs are testing small molecules, antibodies, and RNA-targeting tools aiming to reduce toxic TDP-43 clumps or correct RNA handling. These are not yet approved, but they are directly relevant to ALS10 biology.ATXN2-targeting ASOs (e.g., BIIB105/ION541 — investigational)
Because TDP-43 pathology is common in ALS, lowering ataxin-2 may reduce TDP-43 toxicity in models. Early-phase human studies are ongoing; not standard care yet. (Status evolves as trials report results.)Mesenchymal stem-cell approaches (e.g., NurOwn®)
Trials have shown mixed/negative results; an FDA advisory committee did not support approval in 2023. These treatments are not approved in the U.S. for ALS.Methylcobalamin (ultra-high-dose, early ALS)
In Japan, ultra-high-dose IM methylcobalamin gained approval after a positive trial in early-stage ALS. It is not an immune booster, but may support nerve resilience/regeneration pathways; availability varies by country.Edaravone (antioxidant) and future antioxidant platforms
Edaravone is approved (IV or oral). Newer antioxidants and mitochondrial agents are being studied to protect neurons from oxidative damage—supportive, not curative.
Surgeries / procedures
(what is done and why)
Percutaneous Endoscopic Gastrostomy (PEG) / RIG
Procedure: A feeding tube is placed through the abdominal wall into the stomach (endoscopy or radiology).
Why: To keep nutrition, hydration, and medicines safe when swallowing is hard; doing this before breathing capacity falls too low lowers complications.Tracheostomy with invasive ventilation (selected cases)
Procedure: A breathing tube is placed through the neck into the windpipe, connected to a ventilator.
Why: For people who choose long-term ventilator support when non-invasive ventilation is no longer enough; requires full discussion of goals and caregiving needs.Intrathecal baclofen pump implantation
Procedure: A small pump is implanted under the skin with a catheter to the spinal fluid.
Why: For severe spasticity not controlled by pills; enables much lower total doses with fewer whole-body side effects.Botulinum toxin injections to salivary glands
Procedure: Ultrasound-guided injections into parotid/submandibular glands.
Why: To control severe drooling when pills fail; reduces saliva for months.Airway procedures for secretion management
Procedure: In advanced cases, tracheostomy suctioning or bronchoscopy for mucus plugs.
Why: To maintain airway patency and reduce infection risk when cough is absent.
Note: Diaphragm pacing is generally not recommended in ALS due to poor outcomes in studies.
Preventions
(In ALS10 you cannot prevent the gene change, but you can prevent complications and unsafe events)
Timely vaccinations (flu, pneumonia).
Early NIV when tests show breathing weakness.
Early nutrition/PEG planning to avoid severe weight loss or choking.
Fall prevention at home; use proper mobility aids.
Pressure-injury prevention with cushions and frequent position changes.
Aggressive oral care to reduce aspiration pneumonia risk.
Hand hygiene and fast treatment of chest infections.
Energy conservation to avoid exhaustion and injury.
Advance care plans to avoid crisis care that is not aligned with wishes.
Caregiver training for safe transfers, feeding, and device use.
When to see doctors urgently
Choking episodes, frequent coughing with meals, or unintentional weight loss.
Morning headaches, daytime sleepiness, or shortness of breath (especially when lying flat) — could mean breathing weakness that needs NIV.
New falls, new injuries, or rapid loss of function.
Worsening drooling or thick secretions that make breathing or eating unsafe.
Severe mood changes, uncontrolled crying/laughing, or distressing anxiety or depression.
Any drug side effects (e.g., jaundice on riluzole; allergic reactions on edaravone).
What to eat and what to avoid
Eat more of:
High-calorie, high-protein meals/snacks (nut butters, eggs, yogurt, smoothies).
Soft, moist foods if swallowing is difficult (oatmeal, stews, mashed foods).
Healthy fats (olive oil, avocado, fish) for extra calories.
Hydrating fluids with safe thickness if advised (to prevent dehydration).
Vitamin D/calcium sources to protect bones (per labs and doctor advice).
Avoid or limit:
- Dry, crumbly foods (crackers, dry rice) that are easy to choke on.
- Mixed-texture foods (soups with chunks) if aspiration risk is high.
- Alcohol that worsens balance and sleep/breathing.
- Very large meals that increase fatigue and reflux.
- Unproven “miracle” supplements that claim to cure ALS — they can waste money or interact with medicines.
FAQs
1) What exactly is ALS10?
A genetic form of ALS caused by mutations in TARDBP. It damages motor neurons, leading to progressive muscle weakness. Some families also show features of frontotemporal dementia.
2) Is ALS10 inherited?
Often yes — typically autosomal dominant. A person with a TARDBP mutation has a 50% chance of passing it to each child. Genetic counseling is recommended.
3) How is ALS10 diagnosed?
By clinical exam and nerve tests typical of ALS, plus genetic testing showing a TARDBP mutation.
4) Is there a cure?
No cure yet. But riluzole and edaravone can modestly slow decline, and NIV and PEG improve quality and sometimes length of life when used at the right time.
5) What about AMX0035 (RELYVRIO/ALBRIOZA)?
It was withdrawn from U.S. and Canadian markets in April 2024 after a negative phase 3 trial; not available for new patients there.
6) Are there gene therapies for ALS10?
Not yet. Tofersen works for SOD1-ALS, not TARDBP. Research is underway to target TDP-43/TARDBP biology.
7) How does NIV help?
It supports breathing muscles, improves sleep and daytime energy, and has been shown in a randomized trial to improve survival (especially if bulbar function is fair).
8) When should a feeding tube be considered?
When weight loss, dehydration, or aspiration risk rises — earlier placement (often while FVC ≥50%) reduces complications.
9) Can exercise help?
Yes — gentle, paced exercise can help flexibility and mood. Over-exertion is avoided; a therapist sets a safe plan.
10) How do we manage drooling?
Start with non-drug methods, then try glycopyrrolate or scopolamine; consider botulinum toxin to salivary glands if needed.
11) What about muscle cramps?
Mexiletine can reduce cramps in many patients (doctor supervision needed). Stretching, hydration, and magnesium may help some.
12) What mental health support is useful?
Counseling, support groups, and treatment for depression/anxiety improve coping and quality of life.
13) Do supplements work?
No supplement cures ALS. Some support general health; ultra-high-dose methylcobalamin has evidence in early ALS in Japan, but this is specialist-guided and country-specific.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 15, 2025.
